Trendlines 2018 Year-End Results:
Portfolio Value at US$97.2 Million; Cost-Reduction Exceeds Goals

Misgav, Israel and Singapore, 20 February 2019 – The Trendlines Group Ltd. (the "**Company**" and together with its subsidiaries, **"Trendlines"** or the "**Group**"), a leading Israeli investment and innovation commercialization company focused on building value through early-stage, high growth innovation-based medical and agricultural technologies, has announced its financial results for the financial year ended 31 December 2018 **("FY2018")** today.

2018 Group Financial Highlights:

- Ten new portfolio companies established
- Fair Value of Portfolio: US$97.2 million (31.12.2017: US$96.8 million)
- 5 newly-formed portfolio companies are consolidated and not included in US$97.2 million Fair Value of Portfolio
- Total current assets: US$11.8 million (31.12.2017: US$20.4 million)
- Net loss: US$6.3 million (FY2017: Net income US$3.9 million)
- Book value of US$86.0 million as at 31.12.18 (31.12.2017: $92.2 million)

2018 Financial Results

As mentioned in our second quarter ended 30 June 2018 earnings press release, our portfolio value and profitability tend to be "lumpy," as the nature of our business is closely tied to individual pricing and financial events within our portfolio. For FY2018, we reported a net loss of US$6.3 million, compared to a net gain of US$3.9 million in FY2017. The decrease was mainly due to three factors: (1) An aggregate net decrease of US$8.1 million in the fair value of Stimatix GI due to launch delay and due to a tax ruling under which tax payment is deferred until royalties are actually received, rather than immediate tax of the estimated full value of royalties, (2) A decrease of approximately US$2.6 million in the fair market value of various portfolio companies mainly as a result of the completion of fund-raising exercises at less favorable terms to the Company, and general commercial or technological difficulties demonstrated in some portfolio companies; and (3) the write-off of five portfolio companies of approximately US$3.2 million. The loss in fair market value of investments in portfolio companies was partially offset by: An aggregate net increase of US$7.5 million in the overall fair market value of various portfolio companies due to factors such as the terms on which each portfolio company completed its fund-raising exercises, and each portfolio company's commercial or technological progress.

In October 2017, Trendlines announced a cost reduction plan for FY2018 ("Cost Reduction Program"). The Company exceeded the goals with operating, general and administrative expenses decreasing by approximately US$2.2 million or 25.45%, with total expenses at US$8.3 million in FY2018, compared to US$10.1 million in FY2017.

Current assets were US$11.8 million as at 31 December 2018, compared to US$20.4 million as at 31 December 2017. The fair value of portfolio companies was US$97.2 million as at 31 December 2018, compared to a portfolio value of US$96.8 million as at 31 December 2017.

Corporate/Business Developments:

- Disclosed the identity of our Most Valuable Portfolio Company as Stimatix GI Ltd. and that the company's assets had been acquired by B. Braun Medical SAS, a subsidiary company of B. Braun. Product launch, which was delayed to allow for product enhancement, began in 2018 and remains on track for worldwide rollout in accordance with updated worldwide rollout plans.
- Trendlines entered into an MOU with Nutreco NuFrontiers, the strategic innovation and investment division of Nutreco, a global leader in animal nutrition and aqua feed.
- Signed a cooperation agreement with Sirius VC, an investment group from Brazil
- Entered into an MOU between Trendlines Medical Singapore and A*ccelerate Technologies to jointly develop and commercialize medical technologies
- Established ten new portfolio companies, including 4 companies developing inventions from Trendlines Labs, and IBI-Ag, the first investee of the Bayer Trendlines Ag Fund.
- Twenty portfolio companies raised a total of US$18.7 million, including raises from strategic partners Johnson & Johnson Innovation and Nutreco NuFrontiers.
- Exceeded goals for Cost Reduction Program for 2018.
- Announced intention to launch Agrifood Tech Innovation Center in Singapore

Post Year-end Developments

- Announced the fruits of a collaboration effort between Trendlines Medical Singapore Pte. Ltd., National Healthcare Group, and A*ccelerate with the establishment and development of two medical portfolio companies
- Announced management changes for 2019
- Announced successful first in human case for portfolio company Leviticus Cardio Ltd.'s paradigm-shifting wireless heart pump system

Commenting on corporate progress, Chairman and CEO Steve Rhodes remarked, "While our overall financial results reported a loss for 2018 of US$6.3 million, this is principally a technical write-down of our Stimatix shares for US$ 8.1 million. Moreover, 2018 saw the accomplishment of a number of strategic goals. We started 10 new companies, bringing the total number of portfolio companies, net of write-offs and exits, to 53. In 2018, twenty of our portfolio companies raised over US$18 million in follow-on investments. As reflected in the 2019 MBO plan, we are planning to focus on building value for our existing companies, with a reduced emphasis on starting new companies in 2019."

Focusing on the Group's increasing partnership network, Chairman and CEO Todd Dollinger said "Trendlines Medical Singapore has invested in six companies so far, while we established two strategic partnerships with Singaporean entities."

"Partnership with multinational corporations plays a vital role at Trendlines; in 2018, we continued to establish collaborations with multinational corporations for us and our portfolio companies," added Todd. "OrthoSpin Ltd. and ViAqua Therapeutics ltd. received investments during 2018 from strategic partnerships previously established by Trendlines."

”Trendlines has established itself as a leader in agrifood tech investing internationally and, on 24 September 2019, we will be holding the 6th AgriVest Conference, highlighting the Israeli agrifood tech ecosystem; we invite investors to come and hear from agrifood tech companies and meet the Trendlines’ team.”

For full financial information, please see our announcement to the SGX: Unaudited Financial Statement for the Financial Year Ended 31 December 2018. Management will record a presentation of the financial results and business developments for the fourth quarter ended 31 December 2018, as well as respond to pre-received questions from analysts and investors. The recording will be posted to the Trendlines’ investors website on Thursday, 21 February 2019. Questions regarding the FY2018 financial results can be sent to investors@trendlines.com.

About The Trendlines Group Ltd.
Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines’ shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

-The End-

Investor Contact Information
Israel
Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore
Reyna MEI, Financial PR
reyna@financialpr.com.sg
Tel: +65.6438.2990

This press release has been prepared by The Trendlines Group Ltd. (the “Company”) and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”) for compliance with the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Associate Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg)